|TAS015-C01||SARS-CoV-2 Spike protein RBD||10ug|
|TAS015-C02||Anti-SARS-CoV-2 Antibody (Control, IgG2)||10ug|
|TAS015-C03||HRP-Mouse anti-Human IgG2 HRP||20ug|
Upon receipt, please store the lyophilized products at -20℃. After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable under storage conditions:
12 months in sealed state;
Used within 3 months after opening.
Your experiment will include 6 simple steps:
a) Coat the plate with SARS-CoV-2 Spike protein RBD.
b) Wash the plate with universal ELISA buffer and block the plate with the blocking buffer.
c) Add your sample to the plate, take the Anti-SARS-CoV-2 antibody as Control sample. The samples and Control sample are diluted by Blocking / Dilution Buffer.
d) Add diluted Secondary antibody HRP-Mouse-Anti-Human IgG2 to the plate. The Secondary antibody is diluted by Blocking / Dilution Buffer.
e) Wash the plate and add TMB or other colorimetric HRP substrate.
f) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.